本季度信息
截至2026年6月30日，堃博医疗-B录得营收328.8万美元，同比大幅增长99.0%。同期毛利为223.1万美元，同比增长83.8%，毛利率由上年同期的67.9%升至73.5%。
经调整净亏损为798.2万美元，对比2025年同期的695.6万美元下降幅度为14.7%。销售及分销费用为373.6万美元，同比上涨13.0%；研发投入为403.0万美元，同比减少9.6%。
经营现金流方面，报告期内经营活动现金流净流出为388.3万美元，较上年同期的474.2万美元继续改善。
本季度信息
截至2026年6月30日，堃博医疗-B录得营收328.8万美元，同比大幅增长99.0%。同期毛利为223.1万美元，同比增长83.8%，毛利率由上年同期的67.9%升至73.5%。
经调整净亏损为798.2万美元，对比2025年同期的695.6万美元下降幅度为14.7%。销售及分销费用为373.6万美元，同比上涨13.0%；研发投入为403.0万美元，同比减少9.6%。
经营现金流方面，报告期内经营活动现金流净流出为388.3万美元，较上年同期的474.2万美元继续改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.